New combo therapy aims to tame rare bleeding disorder
NCT ID NCT07421167
First seen Feb 23, 2026 · Last updated May 13, 2026 · Updated 13 times
Summary
This study tests whether adding the drug ianalumab to a standard platelet-boosting therapy is tolerable for adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants must have tried at least one prior treatment and be on a stable dose of a platelet-boosting drug. The main goal is to see how many people can stay on the combination without serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
DH Cancer Research Center LLC
RECRUITINGMargate, Florida, 33063, United States
Contact Email: •••••@•••••
Contact
-
Hope And Healing Care
RECRUITINGHinsdale, Illinois, 60521, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.